QuantumDx Developing Biochips for HIV, TB, and Warfarin Sensitivity Testing
October 25, 2011
QuantumDx Developing Biochips for HIV, TB, and Warfarin Sensitivity Testing
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- QuantumDx Leading $4.5M UK-Supported Project to Develop Rapid Molecular Tumor Profiling Device
November 8, 2012 / PCR Insider - Point-of-Care Malaria MDx Project Funded by EU and Using QuantuMDx Technology is Ahead of Schedule
April 25, 2013 / PCR Insider - MDx Firm QuantuMDx Buys NorthGene
March 1, 2013 / GenomeWeb Daily News - QuantumDx Expands Nanosys Biosensor License; Preps POC MDx System for Market
October 13, 2011 / PCR Insider - At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News